SEC Issues Alert About Churning
Yesterday, the SEC issued an investor alert about “churning.” This alert was issued alongside a churning case that the SEC also filed in federal court yesterday. Yesterday’s news may be of interest to a potential SEC whistleblower or an SEC whistleblower lawyer, as it provides yet another example of the kinds of cases that the SEC brings.
Relevance of the alert for an SEC whistleblower or SEC whistleblower lawyer
In its alert, the SEC defines churning as occurring “[w]hen a broker engages in excessive buying and selling (i.e., trading) of securities in a customer’s account without considering the customer’s investment goals and primarily to generate commissions that benefit the broker.”
The alert includes churning under the category of “excessive trading.” According to the SEC alert, some flags that churning or excessive trading may be occurring include:
- unauthorized trades,
- frequent in-and-out purchases and sales that are inconsistent with the customer’s investment goals and risk tolerance, and
- excessive fees.
If an SEC whistleblower or their SEC whistleblower lawyer believes that a broker or broker dealer firm has been engaging in excessive trading or churning, the alert says that they should “submit a complaint in writing to the brokerage firm and to the SEC or FINRA.” (Note that a complaint to FINRA may not satisfy the requirements of the SEC whistleblower program; a complaint to the SEC will.)
SEC charges brokers with $1.37MM churning fraud
The SEC’s alert mentions two churning cases, the most recent one being SEC v. Dean and Fowler, filed in U.S. District Court on the same day as the alert.
Allegedly, the two brokers named in the court Complaint engaged in churning and excessive in-and-out trading in customer accounts. According to the Complaint, the scheme caused investors losses totaling $1,374,202.
In a press release about the case, Andrew M. Calamari, the Director of the SEC’s Regional Office stated “This case marks another chapter in the SEC’s pursuit of brokers who deploy excessive trading as a strategy in customer accounts to enrich themselves at customers’ expense.” Mr. Calamari is also a Co-Chair of the SEC Enforcement Division’s Broker Dealer task force.
* * *
About the Pickholz Law Offices LLC
The Pickholz Law Offices LLC is a law firm that focuses on representing clients involved with investigations conducted by the U.S. Securities and Exchange Commission, FINRA, and other securities regulators.
The Pickholz Law Offices has represented employees, officers, and others in SEC whistleblower cases involving financial institutions and public companies listed in the Fortune Top 10, Top 20, Top 50, Top 100, Top 500, and the Forbes Global 2000. We were the first law firm ever to win an SEC whistleblower award for a client on appeal to the full Commission in Washington. Inside Counsel magazine named this achievement one of the five key events of the SEC whistleblower program. Examples of the Firm’s SEC whistleblower cases are available here.
In addition to representing SEC whistleblowers, since 1995 the Firm’s founder, Jason R. Pickholz, has also represented many clients in securities enforcement investigations conducted by the SEC, FINRA, the U.S. Department of Justice and US Attorney’s Offices, State authorities, and more. Examples of some of the many securities enforcement cases that Mr. Pickholz has been involved with are available here.
You can see what actual clients have had to say about The Pickholz Law Offices by going to the Client Reviews page on our website or by clicking here.
How to Contact the Pickholz Law Offices LLC
If you would like to speak with a securities lawyer or SEC whistleblower attorney, please feel free to call Jason R. Pickholz at 347-746-1222.
The Pickholz Law Offices remains open and will be fully operational through teleworking while we all grapple with this terrible pandemic. We hope that all of our clients, colleagues, friends, and their families remain safe and healthy. Our thoughts and prayers go out to everyone who has been affected by COVID-19.